Novel Ligand-Targeted Immunotherapy for the treatment of Human Respiratory Syncytial Virus

Respi-DART 2024
Written By Jeffery J Niesen

Jeffery J Niesen

Department of Chemistry, Purdue University and Eradivir Inc

Sign up to read this post
Join Now
Previous

In vitro antiviral activity of obeldesivir and GS-441524 in combination with oral SARS-CoV-2 therapeutics nirmatrelvir/ritonavir or molnupiravir
Next

A Small Molecule Based Bispecific Antigenic Immunotherapy for the treatment of Dengue